BioSpace News Archive

HotSpot Therapeutics, Inc. today announced the presentation of preclinical data from the Company’s highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program in an oral presentation at the 2023 American Society of Hematology (ASH) Annual Meeting.

Remix Therapeutics today announced that the Company will be participating in the 6th Annual RNA-Targeted Drug Discovery & Development Summit taking place December 12-14, 2023.

Hemab Therapeutics announced today that it has completed Phase 1, the single ascending dose part, and transitioned to Phase 2, the multiple ascending dose part, of its Phase 1/2 clinical study of HMB-001 in Glanzmann Thrombasthenia (GT), a platelet disorder that causes severe, potentially life-threatening bleeding episodes.

Acurx Pharmaceuticals, Inc. today announced positive Phase 2b results showing 100% of CDI patients who had CC with ibezapolstat, the company’s late-stage antibiotic candidate, also had SCC.

Electra Therapeutics, Inc. today announced the appointment of Kathy Dong, PharmD, MBA, as President and Chief Executive Officer.

Electra Therapeutics, Inc. announced the presentation of the first clinical data for ELA026, the company’s lead candidate in development for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening inflammatory disease.

2seventy bio, Inc . (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego.

Regeneron Pharmaceuticals, Inc. announced its inclusion on the Dow Jones Sustainability World Index for the fifth consecutive year, alongside its fourth consecutive inclusion on the Dow Jones Sustainability North America Index.

CalciMedica Inc. today announced that its collaborator, St. Jude Children’s Research Hospital (SJCRH), presented data from the initial cohort of the Phase 1/2 CRSPA study of Auxora™ (zegocractin injectable emulsion) in asparaginase-induced pancreatic toxicity (AIPT).

Syndax Pharmaceuticals today announced data from multiple trials of revumenib in combination with standard of care agents in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2r) relapsed/refractory (R/R) acute leukemias.